Startup profile · funding coverage
Aevius funding, valuation and investors
Mass General Brigham spinout building longitudinal patient-data foundation models for health systems, payers and life-sciences companies.
Verified company research · funding, investors and latest developments
Keep track of Aevius
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Financing (series undisclosed by issuer)
$22M · November 17, 2026
Latest known valuation
Undisclosed
Financing (series undisclosed by issuer) · November 17, 2026
Total disclosed equity funding
$22M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
Stage not recorded · Boston, Massachusetts, United States
Investors in latest funding
Lead: Insight Partners
Overview
Aevius Labs is a Boston Mass General Brigham spinout founded by Rowland Pettit (CEO), Ming Yang/Max Lu (CTO), Faisal Mahmood and Long Phi Le, all of whom helped build Modella AI before its acquisition by AstraZeneca. The previous acquisition's consideration is undisclosed. Aevius announced $22M of financing led by Insight Partners on Nov 17 2026; the issuer did not identify a series, valuation or exact legal closing date.
The new company proposes foundation models unifying structured medical records, text, imaging and other specialty modalities into a refreshable longitudinal representation of patients for research, care planning, cohort studies and payer analysis. This is not proof of regulatory approval, clinically validated prediction, broad deployment or revenue.
Pricing, customers, prospective validation, fairness and independently measured benefit remain undisclosed.
Why Aevius is interesting
An Insight Partners-led $22M company financing announced Nov 17 2026 addresses multimodal patient data, but its original issuer release does not identify a round series, valuation, clinical-validation study or paying customers.
Product & use cases
Illustrative health-system research deployment, not hands-on testing: 1. Confirm patient-data permissions, secure deployment and appropriate uses. 2. Normalize consented lab results, notes, images and longitudinal records with identifiers. 3. Aevius aims to construct updatable patient-history representations from those inputs. 4. Authorized analysts could ask cohort, risk and trajectory questions using those representations. 5. Independently test outputs on separate hospital cohorts, and put clinicians/privacy teams in the approval loop before any clinical use. The company has not published a production integration tutorial, commercial tariff, regulated-diagnostic approval or external-validation evidence.
- Hospital analytics team seeks cohorts with comparable longitudinal clinical characteristics for retrospective studies.
- Life-sciences sponsor examines patient trajectories or candidate biomarkers for trial design, with independent validation.
- Payer population-health unit tests risk stratification, including bias, calibration and privacy safeguards.
Key facts
- Company-issued Nov 17 2026: $22M funding led by Insight Partners, formal round series not issuer-confirmed.
- Mass General Brigham spinout; founders previously built Modella AI, acquired by AstraZeneca for an undisclosed amount.
- A proposed reusable patient representation across time, notes, imaging and medical records, not an approved diagnostic.
- No external predictive benchmarks, deployed customer list, clinical endpoint validation, pricing or audited revenue provided.
Funding history (newest first)
Financing (series undisclosed by issuer)
2026-11-17 $22M Valuation: UndisclosedSource: Read source · businesswire.com
Investors in our directory
Funds linked from Aevius's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Reusing one patient representation across many downstream analytics tasks could reduce repetitive data joining, but the economic and clinical advantage is currently unproven.
Prospective clinical improvement cannot be inferred from patient representations. Hospital-to-hospital generalization, multimodal missingness, bias, consent, deidentification, model drift and explainability need evaluation. The issuer supplies no standardized benchmark or clinical approval, and company partnership invitations do not establish paid deployments. No source-backed evidence currently establishes superiority over Dyania, Owkin, Tempus or conventional clinical analytics.
-
Dyania Health direct
Clinical text and medical-record review for research and operations.
-
Owkin direct
Multimodal biomedical AI and research data networks.
-
Tempus AI alternative
Molecular and clinical precision-medicine data tools.
-
Carta Healthcare alternative
Registry abstraction and trial-identification workflows.
-
Health-system FHIR/data-warehouse analytics alternative
In-house data preparation and validated task-specific models.
Market / IPO context
Editorial / static context — not a live quote.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.